Navigation Links
S1P1 Agonists are Currently Indicated For Treatment of Multiple Sclerosis

WELLESLEY HILLS, Mass.,  Oct. 18, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix") announced today that the S1P1 lead compounds, AMG 369 and AMG 277, will be offered December 8, 2011 in a sealed bid sale.  S1P1 agonists are currently indicated for treatment of multiple sclerosis ("MS").

MS is the second most common cause of disability in young adults (after trauma) and affects approximately 350,000 – 450,000 people in the US and 1-2 million people worldwide.  The major unmet need in MS is agents with better safety and efficacy, especially in terms of halting the progression of disease and preventing or slowing disability.  Until recently, treatment for MS was generally directed in three areas; 1) reduction of acute exacerbations, 2) reduction of relapses/disability progression, or 3) symptomatic relief.  All of these first or second line therapies required injection or infusion, including the number one selling MS drug, Copaxone, which had sales of $2.6 Bil in 2010 and will face generic competition in 2014.  Worldwide sales for all MS drugs were $11.5 Bil in 2010 and expected to grow at a CAGR of 6% to almost $19 Bil by 2016.

Information above per EvaluatePharma®, Available WW Sales for Autoimmune Disorders and Multiple Sclerosis, Aug. 4, 2011.

Assets included in the sale include preclinical and toxicology data related to AMG 277, AMG 369 and six backup compounds, existing inventory of these compounds (API), and related patent portfolio.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's office – or 781-237-8840; upon receipt of the executed CDA, applicants will receive a bid package, to be completed and returned by December 8, 2011.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts.  He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.  His most recent Assignments for the Benefit of Creditors in the biotech filed include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc. and Source MDx.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or

SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations
2. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
3. Robotic Surgery Expert Dr. David Samadi, MD Discusses FDA Warnings on the Effect of GnRH Agonists
4. Use of Vitamin K Antagonists in the Treatment of Atrial Fibrillation is Driven by the Availability of an Oral Formulation, Cost and Widespread Inclusion on Guidelines and Formularies
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. Par Pharmaceutical Announces Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010
7. Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Note
8. New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS
9. New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes
10. NACDS, NCPA: Victory for Patients, Pharmacy as CMS Moves to Withdraw Provisions of AMP Rule Currently Blocked by Injunction
11. Intermittent Catheter Market Currently Valued at $230 Million and Set to Double by 2014
Post Your Comments:
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):